StockNews.com Begins Coverage on Regulus Therapeutics (NASDAQ:RGLS)

Investment analysts at StockNews.com began coverage on shares of Regulus Therapeutics (NASDAQ:RGLS) in a research note issued to investors on Monday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Other equities research analysts also recently issued reports about the company. Canaccord Genuity Group decreased their target price on Regulus Therapeutics from $12.00 to $11.00 and set a “buy” rating on the stock in a research report on Tuesday, March 19th. Wells Fargo & Company boosted their target price on Regulus Therapeutics from $2.00 to $3.00 and gave the stock an “equal weight” rating in a research report on Wednesday, March 13th. Leerink Partnrs reiterated an “outperform” rating on shares of Regulus Therapeutics in a research report on Monday, March 18th. SVB Leerink initiated coverage on Regulus Therapeutics in a research report on Monday, March 18th. They issued an “outperform” rating and a $6.00 target price on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $9.00 target price on shares of Regulus Therapeutics in a research report on Monday, March 25th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $7.25.

Regulus Therapeutics Stock Up 1.1 %

Shares of Regulus Therapeutics stock opened at $2.70 on Monday. The stock’s 50-day simple moving average is $1.94 and its 200-day simple moving average is $1.54. Regulus Therapeutics has a 52 week low of $0.85 and a 52 week high of $3.79. The company has a market capitalization of $176.74 million, a price-to-earnings ratio of -1.70 and a beta of 1.56.

Regulus Therapeutics (NASDAQ:RGLS) last announced its quarterly earnings data on Thursday, March 21st. The biopharmaceutical company reported ($0.40) EPS for the quarter, meeting the consensus estimate of ($0.40). On average, equities analysts expect that Regulus Therapeutics will post -0.52 earnings per share for the current year.

Institutional Investors Weigh In On Regulus Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. Exome Asset Management LLC bought a new stake in Regulus Therapeutics during the fourth quarter worth approximately $228,000. Victory Capital Management Inc. increased its stake in Regulus Therapeutics by 16.5% during the fourth quarter. Victory Capital Management Inc. now owns 271,736 shares of the biopharmaceutical company’s stock worth $348,000 after acquiring an additional 38,529 shares during the last quarter. FMR LLC grew its stake in shares of Regulus Therapeutics by 32.4% during the third quarter. FMR LLC now owns 2,922,600 shares of the biopharmaceutical company’s stock valued at $4,033,000 after buying an additional 716,000 shares during the last quarter. Renaissance Technologies LLC grew its stake in shares of Regulus Therapeutics by 18.8% during the second quarter. Renaissance Technologies LLC now owns 46,100 shares of the biopharmaceutical company’s stock valued at $68,000 after buying an additional 7,300 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Regulus Therapeutics by 51.0% during the second quarter. Geode Capital Management LLC now owns 112,622 shares of the biopharmaceutical company’s stock valued at $166,000 after buying an additional 38,049 shares during the last quarter. 92.38% of the stock is owned by institutional investors.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease.